|
This two-day biologics formulation event will take place Thursday and Friday and will be a part of CHI’s 8th Annual PepTalk – The Definitive Protein-Focused Event.
“Current Trends in Dosage Form Development and Biologics Formulation --
Addressing Challenges in Stability Testing, Forced Degradation, Protein
Aggregation and Manufacturing” will feature novel case studies, in-depth presentations and interactive panels from industry thought leaders. It is perfect for those new to the field, as well as those who require in-depth analysis of the latest trends, technologies, and techniques.
Featured Presentations
 Potential Impact of Formulations on the Immunogenicity of Biologics
Harald Kropshofer, Ph.D., Global Coordinator & Head Immunosafety, Global Nonclinical Safety,
F. Hoffmann La Roche AG
 Current Trends in Biologics Formulations:
Development in Oncology versus Infl ammation,
New Development Tools, and Convenience Devices
Palani Palaniappan, Ph.D., Senior Director, Pharmaceutical Sciences, Millennium
Pharmaceuticals, a Takeda Oncology Company
 PEGylation Strategies for Improved Protein Formulations
Tim Riley, Vice President, PEGylation Research, Nektar
 High-Throughput Analytics Lab (HTL) for the Market Formulation Development of Antibodies
Kurt Forrer, Ph.D., Senior Fellow, Novartis Pharma AG
 The Discovery-Development Interface, an Important Relationship in Successful
Dosage Form Design for Biotherapeutics
Kevin King, Ph.D., Director, Formulation Development and Product Enhancements,
Global Biologics, Pfizer
 Improving Biotherapeutic Convenience and Compliance through Delivery
Technologies
Christopher A. Rhodes, Ph.D., Executive Director, Pharmaceutical Sciences, Amylin Pharmaceuticals
PLUS!
Pre-Conference Short Courses
SC1: Avoid Leachables, Extractables, and
Other Hazards in Parenteral Packaging
SC2: Elements of a High Quality Aseptic Filling Process
Overview
| Short Courses | Day
1 | Day 2 | Download Brochure
|
